about
Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemiaSupportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries.Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.Primary Cutaneous Lymphomas in Children and Adolescents.Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia.Anaplastic Large Cell Lymphoma in Central America: A Report From the Central American Association of Pediatric Hematology Oncology (AHOPCA).Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymDNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.Oral Nutritional Supplementation in Children Treated for Cancer in Low- and Middle-Income Countries Is Feasible and Effective: the Experience of the Children's Hospital Manuel De Jesus Rivera "La Mascota" in Nicaragua.[Recent advances and future directions in CAR-T cell therapy in pediatric oncology]Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacyGenetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencingPrimary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescentsChimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia
P50
Q28245060-B2B8ED5F-2A6F-4C3E-B987-A32E5A5D0BCFQ33423131-EFCA3850-BA85-4594-BC73-CF92D02B41A1Q34644733-B0FF3D7D-4150-4070-AE66-84B4AA304686Q36134458-7FDBE380-95D4-470B-BDED-852247BF4B0BQ38643300-EDF07BF8-08F8-4112-A729-BB22B997455BQ38748699-EC0AFC05-CAD0-416C-8BA0-C086231B31A6Q38845166-E3C02E39-B5FF-4487-9585-8DAB07075E76Q38892345-02A23631-78D1-4476-8BFA-F7960A6121A7Q40643182-C262AD3E-78B6-4C2C-8271-A5F1892E37DCQ40912836-F52037ED-6064-4528-8DFD-FA98780DA1D3Q42208321-4F081925-EB6C-455F-A3E1-A4F031AC9B87Q47199612-BE706AE4-EB00-46BE-96F2-FF33B2C16EE0Q47820469-BE2B3830-3C93-4FD5-AD96-FB7B0202D9EEQ52656723-20E8E168-B584-4077-B07F-046F054818BBQ53819925-5289BF85-22E9-423C-8E4F-717AD90E38A8Q64925014-F151A40C-FCF5-48DC-A9DF-7FDAA1406540Q90981984-6A216CEA-35CE-4B22-A06F-0D754728A5D8Q91165029-725437CB-BA3C-4189-A934-D6AD465828F8Q91326518-57AE71C2-15A7-43AB-9FD1-FCA49D11847FQ92206209-72ABC1F7-0521-4638-A82D-2C8F3B569986Q92337105-09098B96-99B8-42D0-B8E8-2BF00FF4372E
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Francesco Ceppi
@en
Francesco Ceppi
@nl
type
label
Francesco Ceppi
@en
Francesco Ceppi
@nl
prefLabel
Francesco Ceppi
@en
Francesco Ceppi
@nl
P31
P496
0000-0002-9665-3190